Goldman Sachs Group Inc. Decreases Holdings in GRAIL, Inc. $GRAL

Key Points

• Goldman Sachs Group Inc. reduced its stake in GRAIL, Inc. by 39.0%, holding approximately $662,000 worth of shares post-sale.
• GAMMA Investing LLC significantly increased its position in GRAIL by 4,102.5% during the first quarter, while other funds also initiated new stakes.
• GRAIL's recent earnings report showed a loss per share of ($3.18), missing expectations, with revenues falling short of estimates at $35.54 million.

Goldman Sachs Group Inc. cut its stake in shares of GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 39.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 25,929 shares of the company's stock after selling 16,565 shares during the period. Goldman Sachs Group Inc. owned about 0.07% of GRAIL worth $662,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of GRAIL by 4,102.5% during the 1st quarter. GAMMA Investing LLC now owns 25,131 shares of the company's stock valued at $642,000 after acquiring an additional 24,533 shares during the period. Wealth Enhancement Advisory Services LLC bought a new stake in shares of GRAIL during the 1st quarter valued at $719,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of GRAIL during the 4th quarter valued at $1,201,000. Two Sigma Investments LP bought a new stake in shares of GRAIL during the 4th quarter valued at $1,725,000. Finally, Two Sigma Advisers LP bought a new stake in shares of GRAIL during the 4th quarter valued at $345,000.

GRAIL Price Performance

Shares of GRAL stock opened at $46.58 on Thursday. GRAIL, Inc. has a 1 year low of $12.33 and a 1 year high of $63.99. The firm has a fifty day moving average price of $35.79 and a 200-day moving average price of $35.73. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -3.55 and a beta of 3.18.

GRAIL (NASDAQ:GRAL - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.14) by ($0.04). GRAIL had a negative net margin of 329.86% and a negative return on equity of 16.64%. The business had revenue of $35.54 million for the quarter, compared to the consensus estimate of $37.57 million. Equities research analysts expect that GRAIL, Inc. will post -15.15 EPS for the current year.

Insider Activity

In related news, major shareholder Chun R. Ding sold 339,800 shares of the company's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $49.53, for a total value of $16,830,294.00. Following the completion of the transaction, the insider owned 3,305,055 shares of the company's stock, valued at approximately $163,699,374.15. This represents a 9.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, President Joshua J. Ofman sold 4,202 shares of the company's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $32.02, for a total transaction of $134,548.04. Following the completion of the transaction, the president directly owned 487,874 shares of the company's stock, valued at $15,621,725.48. This represents a 0.85% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 361,694 shares of company stock valued at $17,780,266 in the last 90 days. Company insiders own 1.85% of the company's stock.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.